Recent in vivo investigation points to low levels of tumor-infiltrating dendritic cells (DCs) as a reason for limited response to anti-PD-1/PD-L1 mAbs in MSS tumors. This evidence concerns the gene PDCD1 and Marinesco-Sjogren syndrome.